Core Viewpoint - The innovative pharmaceutical stocks have shown a rebound, with notable increases in share prices for several companies, driven by recent policy developments and market dynamics [1] Group 1: Stock Performance - Gilead Sciences-B (01672) increased by 10.26%, reaching HKD 13.11 [1] - Kangfang Biotech (09926) rose by 4.15%, reaching HKD 123.1 [1] - Zai Lab (09688) saw a 3.36% increase, reaching HKD 15.69 [1] - Xiansheng Pharmaceutical (02096) grew by 2.9%, reaching HKD 13.48 [1] Group 2: Policy Developments - In November, the National Healthcare Security Administration initiated negotiations for the 2025 National Basic Medical Insurance Drug List and the pricing consultation for the commercial insurance innovative drug list [1] - The fourth batch of traditional Chinese medicine centralized procurement was launched, and new policies regarding medical devices were introduced in Beijing [1] - The State Council meeting outlined plans to promote provincial-level coordination of basic medical insurance [1] Group 3: Market Insights - Bohai Securities highlighted the importance of the upcoming release of the new basic medical insurance drug list and the first commercial insurance innovative drug list in early December, indicating potential investment opportunities in related pharmaceutical companies [1] - Zhongyou Securities noted that despite a temporary vacuum in domestic BD outbound transactions, several collaborations with multinational corporations (MNCs) have emerged since Q4, reflecting the recognition of domestic innovative drug companies' R&D capabilities [1] - The strong competitive advantages of China's innovative drug industry, including the capacity of the industry chain, pipeline quantity and quality, and R&D efficiency, are expected to drive long-term industry trends [1]

Core Viewpoint - The Hong Kong innovative drug concept stocks have shown a rebound today, indicating a positive market sentiment towards this sector [1] Company Performance - Gilead Sciences-B (01672.HK) increased by 10.26%, reaching HKD 13.11 [1] - CanSino Biologics (09926.HK) rose by 4.15%, trading at HKD 123.1 [1] - Zai Lab (09688.HK) saw a gain of 3.36%, with a price of HKD 15.69 [1] - Ascletis Pharma (02096.HK) grew by 2.9%, priced at HKD 13.48 [1]

Core Viewpoint - The innovative drug sector is experiencing a rebound, with notable stock price increases for several companies following recent policy developments in China's healthcare system [1] Group 1: Stock Performance - Gilead Sciences-B (01672) increased by 10.26%, reaching HKD 13.11 [1] - Kangfang Biotech (09926) rose by 4.15%, priced at HKD 123.1 [1] - Zai Lab (09688) saw a 3.36% increase, trading at HKD 15.69 [1] - Xiansheng Pharmaceutical (02096) grew by 2.9%, now at HKD 13.48 [1] Group 2: Policy Developments - In November, the National Healthcare Security Administration initiated negotiations for the 2025 National Basic Medical Insurance Drug List and the pricing of innovative drugs for commercial insurance [1] - The fourth batch of traditional Chinese medicine procurement has commenced, and new policies regarding medical devices have been introduced in Beijing [1] - The State Council has outlined plans to advance provincial-level coordination of basic medical insurance [1] Group 3: Investment Opportunities - Bohai Securities highlighted the importance of the upcoming release of the new basic medical insurance drug list and the first commercial insurance innovative drug list in early December, suggesting potential investment opportunities in related pharmaceutical companies [1] - Zhongyou Securities noted that despite a temporary lull in domestic BD (business development) transactions, there have been multiple collaborations with multinational corporations (MNCs) since Q4, indicating ongoing interest in domestic innovative drug companies [1] - The purchasing behavior of overseas MNCs is seen as a validation of the innovative research capabilities of domestic companies, reflecting China's strong competitive advantages in the global innovative drug industry [1]

Group 1 - The Hong Kong innovative drug sector showed strength in early trading, with companies like Kangfang Biopharma and Zai Lab rising over 3% [1] - The Hang Seng Innovative Drug ETF (159316) saw its index increase by over 1%, reflecting positive market sentiment [1] - Chinese innovative drug development is becoming a significant global player, with increasing overseas licensing transactions driving growth in the sector [1] Group 2 - The pharmaceutical industry is entering a critical phase characterized by "innovation realization + global layout," supported by population and domestic demand, as well as comprehensive manufacturing capabilities [1] - Companies are actively exploring diverse overseas expansion paths, indicating a strategic shift towards international markets [1] - By 2026, opportunities in innovative commercialization, global breakthroughs, policy optimization, and industry mergers and acquisitions are expected to emerge [1] Group 3 - The Hang Seng Hong Kong Stock Connect Innovative Drug Index is one of the first "pure" 100% innovative drug indices, accurately reflecting the overall performance of China's innovative drug companies [1] - The Hang Seng Innovative Drug ETF (159316) is currently the only product tracking this index, providing investors with a convenient way to seize industry development opportunities [1]

Group 1 - The Hang Seng Healthcare Index (HSHCI) has risen by 1.17% as of December 4, 2025, with notable increases in stocks such as InnoCare Pharma (up 4.91%), CanSino Biologics (up 4.65%), and MicroPort Scientific (up 4.51%) [1] - The 11th batch of national centralized procurement results was released on November 7, including 453 products across 55 varieties, with an average price reduction of approximately 75% compared to the highest valid bid [1] - The upcoming ESMO Asia 2025 conference will take place from December 5-7, and the 67th American Society of Hematology (ASH) meeting will be held from December 6-9, which are expected to catalyze data releases in the healthcare sector [1] Group 2 - The top ten weighted stocks in the Hang Seng Healthcare Index (HSHCI) account for 60.48% of the index, including companies like BeiGene, Innovent Biologics, and WuXi Biologics [2] - The Hang Seng Healthcare ETF (159557) closely tracks the HSHCI, providing a market reference for the performance of healthcare securities listed in Hong Kong [2] - Investors without stock accounts can access the Hong Kong healthcare sector investment opportunities through the Hang Seng Healthcare ETF linked fund (018433) [2]

Group 1 - The core viewpoint is that the innovative drug sector is expected to remain the most important investment theme in the pharmaceutical sector for the upcoming year, with significant positive catalysts emerging [2] - The Hong Kong pharmaceutical ETF (159718.SZ) has seen a 0.74% increase, with notable gains in constituent stocks such as Kangfang Biopharma (4.57%), MicroPort Scientific (4.15%), and Zai Lab (3.95%) [1] - The U.S. job market showed a significant decline in November, with private sector jobs decreasing by 32,000, the largest drop in two and a half years, which has heightened expectations for a Federal Reserve interest rate cut [1] Group 2 - The pharmaceutical sector has experienced a 2-3 month adjustment period, leading to a relative low in stock prices, market expectations, and institutional allocations, thus enhancing investment safety margins [2] - Multiple favorable policies are set to be released, including December's medical insurance negotiations and international conferences, which are expected to positively impact the industry [2] - The U.S. biotechnology index (XBI) has risen by 2.84%, reflecting a strong performance in the healthcare sector, with expectations of a gradual recovery in global innovative drug financing and demand [1][2]

Group 1 - The Hong Kong stock market opened slightly higher on December 4, with the Hang Seng Index rising by 0.17% and the Hang Seng Biotechnology Index increasing by over 1% [1] - The Hong Kong Stock Connect Technology ETF (513860) saw a gain of 1.22%, with significant increases in constituent stocks such as Kingsoft Biotechnology and CanSino Biologics, both rising nearly 4% [1] - As of December 3, the Hong Kong Stock Connect Technology ETF (513860) attracted a total of 410 million yuan over the past nine trading days, with a net inflow of 74.36 million yuan on December 2 [1] Group 2 - Guosen Securities emphasizes that AI will remain a key focus through 2026, driven by the need for accelerated domestic hardware production and the expectation of more AI applications being implemented [2] - The Hong Kong Stock Connect Technology ETF (513860) closely tracks the CSI Hong Kong Stock Connect Technology Index, which selects 50 large-cap, high R&D investment, and fast-growing technology companies [2] - The top ten weighted stocks in the index include major players such as Alibaba-W, Tencent Holdings, SMIC, BYD, and Xiaomi Group-W [2]

展望后市，12月医保谈判、商保目录及国际会议等多重利好集中释放；BD交易持续活跃，今年已出现 多笔超10亿美元授权。创新药产业趋势不变，随着行业正向催化的陆续落地，板块情绪也有望逐步恢 复。当前板块已提前调整至半年线，估值具备吸引力，建议关注港股医药ETF(159718)。 12月4日早盘，港股高开，隔夜美股标普生物科技大涨2.84%，港股医药ETF(159718.SZ)高开0.74%。成 分股金斯瑞生物科技(01548)上涨4.15%，康方生物(09926)上涨2.96%，同源康医药-B(02410)上涨 2.82%，再鼎医药(09688)，微创机器人-B(02252)等个股跟涨。 消息面上，美国11月"小非农"创两年半来最大降幅，美联储降息预期进一步升温。最新公布的ADP就业 数据显示，11月私营企业减少3.2万个工作岗位，为2023年3月以来最大降幅，远不及市场预期的增加1 万个。据CME"美联储观察"，美联储12月降息25个基点的概率接近90%。 隔夜美股标普生物科技指数（XBI）大涨2.84%，美股医疗保健年初至今涨幅第一，XBI持续走强创近3 年新高，而海外尤其是美国生物医药投融资金额25Q3呈现 ...

Group 1 - The Hong Kong stock market opened slightly higher on December 4, with the Hang Seng Index rising by 0.17% and the Hang Seng Biotechnology Index increasing by over 1% [1] - The Hong Kong Stock Connect Technology ETF (513860) saw a gain of 0.14%, with notable increases in constituent stocks such as Kingsoft Biotechnology and CanSino Biologics, both rising nearly 4% [1] - As of December 3, the Hong Kong Stock Connect Technology ETF (513860) attracted a total of 410 million yuan over the past nine trading days, with a net inflow of 74.36 million yuan on December 2 [1] Group 2 - Guosen Securities emphasizes that AI will remain a key focus through 2026, driven by the need for accelerated domestic hardware production and the expectation of more AI applications being implemented [2] - The Hong Kong Stock Connect Technology ETF (513860) closely tracks the CSI Hong Kong Stock Connect Technology Index, which selects 50 large-cap, high R&D investment, and fast-growing technology companies as sample stocks [2] - The top ten weighted stocks in the index include major players such as Alibaba-W, Tencent Holdings, SMIC, BYD Company, and Xiaomi Group-W [2]

Core Viewpoint - Zai Ding Pharma (09688.HK) announced the grant of stock options and restricted stock units under its 2024 equity incentive plan, indicating a strategic move to incentivize key personnel and align their interests with the company's performance [1] Group 1 - The company granted a total of 11,800 American Depositary Shares (ADS) stock options to 3 grantees [1] - Additionally, the company awarded a total of 22,665 restricted stock units (RSUs) to 6 grantees [1] - The grants are set to take effect on December 1, 2025, Eastern Time [1]